Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Nov. 3, 2014, 66 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $710.62 to $347,575,500.00.

Highlighted Stocks Traded by Insiders:

Lions Gate Entertainment (LGF) - FREE Research Report

Goldsmith Brian, who is Co- Chief Operating Officer at Lions Gate Entertainment, sold 25,000 shares at $33.02 on Nov. 3, 2014. Following this transaction, the Co- Chief Operating Officer owned 75,200 shares meaning that the stake was reduced by 24.95% with the 25,000-share transaction.

The shares most recently traded at $32.02, down $1.00, or 3.12% since the insider transaction. Historical insider transactions for Lions Gate Entertainment go as follows:

  • 4-Week # shares sold: 287,500
  • 12-Week # shares sold: 606,504
  • 24-Week # shares sold: 606,504

The average volume for Lions Gate Entertainment has been 1.1 million shares per day over the past 30 days. Lions Gate Entertainment has a market cap of $4.5 billion and is part of the services sector and media industry. Shares are up 3.88% year-to-date as of the close of trading on Monday.

Lions Gate Entertainment Corp., an entertainment company, is engaged in motion picture production and distribution, television programming and syndication, home entertainment, family entertainment, digital distribution, new channel platforms, and international distribution and sales activities. The stock currently has a dividend yield of 0.85%. The company has a P/E ratio of 26.7. Currently, there are 9 analysts who rate Lions Gate Entertainment a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LGF - FREE

TheStreet Quant Ratings rates Lions Gate Entertainment as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, good cash flow from operations, expanding profit margins, growth in earnings per share and notable return on equity. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Lions Gate Entertainment Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Owens & Minor (OMI) - FREE Research Report

Sledd Robert C, who is Director at Owens & Minor, sold 6,088 shares at $33.36 on Nov. 3, 2014. Following this transaction, the Director owned 14,022 shares meaning that the stake was reduced by 30.27% with the 6,088-share transaction.

The shares most recently traded at $33.18, down $0.18, or 0.55% since the insider transaction. Historical insider transactions for Owens & Minor go as follows:

  • 4-Week # shares bought: 2,500
  • 4-Week # shares sold: 33,000
  • 12-Week # shares bought: 2,500
  • 12-Week # shares sold: 99,000
  • 24-Week # shares bought: 2,500
  • 24-Week # shares sold: 99,000

The average volume for Owens & Minor has been 486,700 shares per day over the past 30 days. Owens & Minor has a market cap of $2.1 billion and is part of the services sector and wholesale industry. Shares are down 9.41% year-to-date as of the close of trading on Monday.

Owens & Minor, Inc., together with its subsidiaries, operates as a healthcare logistics company. The company offers supply chain assistance to the providers of healthcare services; and the manufacturers of healthcare products, supplies, and devices. The stock currently has a dividend yield of 3%. The company has a P/E ratio of 25.8. Currently, there are no analysts who rate Owens & Minor a buy, 2 analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OMI - FREE

TheStreet Quant Ratings rates Owens & Minor as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Owens & Minor Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Lannett (LCI) - FREE Research Report

Farber David, who is 10% Owner at Lannett, sold 10,000 shares at $55.00 on Nov. 3, 2014. Following this transaction, the 10% Owner owned 48,370 shares meaning that the stake was reduced by 17.13% with the 10,000-share transaction.

The shares most recently traded at $56.74, up $1.74, or 3.07% since the insider transaction. Historical insider transactions for Lannett go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 17,500
  • 12-Week # shares bought: 500
  • 12-Week # shares sold: 37,500
  • 24-Week # shares bought: 500
  • 24-Week # shares sold: 71,000

The average volume for Lannett has been 698,400 shares per day over the past 30 days. Lannett has a market cap of $2.0 billion and is part of the health care sector and drugs industry. Shares are up 73.78% year-to-date as of the close of trading on Monday.

Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of branded pharmaceutical products in the United States. It offers solid oral, extended release, topical, and oral solution finished dosage forms of drugs that address a range of therapeutic areas. The company has a P/E ratio of 35.0. Currently, there are 3 analysts who rate Lannett a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on LCI - FREE

TheStreet Quant Ratings rates Lannett as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Lannett Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null